Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 230 entries
Sorted by: Best Match Show Resources per page
The impact of automation on high-throughput screening.

Methods and findings in experimental and clinical pharmacology

Houston JG.
PMID: 9403856
Methods Find Exp Clin Pharmacol. 1997;19:43-5.

No abstract available.

Cite
Houston JG. The impact of automation on high-throughput screening. Methods Find Exp Clin Pharmacol. 1997;19:43-5
Houston, J. G. (1997). The impact of automation on high-throughput screening. Methods and findings in experimental and clinical pharmacology, 1943-5.
Houston, J G. "The impact of automation on high-throughput screening." Methods and findings in experimental and clinical pharmacology vol. 19 (1997): 43-5.
Houston JG. The impact of automation on high-throughput screening. Methods Find Exp Clin Pharmacol. 1997;19:43-5. PMID: 9403856.
Copy Download .nbib Format: NLM
Soft drug design: general principles and recent applications.

Medicinal research reviews

Bodor N, Buchwald P.
PMID: 10608921
Med Res Rev. 2000 Jan;20(1):58-101. doi: 10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x.

Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metabolism considerations into the drug design process. Soft drugs are new therapeutic agents that undergo predictable metabolism to inactive metabolites...

Cite
Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev. 2000;20(1):58-101doi: 10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x.
Bodor, N., & Buchwald, P. (2000). Soft drug design: general principles and recent applications. Medicinal research reviews, 20(1), 58-101. https://doi.org/10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x
Bodor, N, and Buchwald, P. "Soft drug design: general principles and recent applications." Medicinal research reviews vol. 20,1 (2000): 58-101. doi: https://doi.org/10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x
Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev. 2000 Jan;20(1):58-101. doi: 10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x. PMID: 10608921.
Copy Download .nbib Format: NLM
The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing.

Nature biotechnology

Archer R.
PMID: 10471905
Nat Biotechnol. 1999 Sep;17(9):834. doi: 10.1038/12782.

No abstract available.

Cite
Archer R. The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing. Nat Biotechnol. 1999;17(9):834doi: 10.1038/12782.
Archer, R. (1999). The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing. Nature biotechnology, 17(9), 834. https://doi.org/10.1038/12782
Archer, R. "The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing." Nature biotechnology vol. 17,9 (1999): 834. doi: https://doi.org/10.1038/12782
Archer R. The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing. Nat Biotechnol. 1999 Sep;17(9):834. doi: 10.1038/12782. PMID: 10471905.
Copy Download .nbib Format: NLM
Computer aids in drug design--highlights.

Polish journal of pharmacology

Ghoshal N, Achari B, Ghoshal TK.
PMID: 9112677
Pol J Pharmacol. 1996 Jul-Aug;48(4):359-77.

An outline of some procedures used for computer aided drug design has been given. The emphasis is on lead generation, both primary and secondary, and on current lead optimization processes which rely on an appreciation of ligand-receptor interactions. The...

Cite
Ghoshal N, Achari B, Ghoshal TK. Computer aids in drug design--highlights. Pol J Pharmacol. 1996;48(4):359-77
Ghoshal, N., Achari, B., & Ghoshal, T. K. (1996). Computer aids in drug design--highlights. Polish journal of pharmacology, 48(4), 359-77.
Ghoshal, N, et al. "Computer aids in drug design--highlights." Polish journal of pharmacology vol. 48,4 (1996): 359-77.
Ghoshal N, Achari B, Ghoshal TK. Computer aids in drug design--highlights. Pol J Pharmacol. 1996 Jul-Aug;48(4):359-77. PMID: 9112677.
Copy Download .nbib Format: NLM
For medicinal purposes.

Nature

Petsko GA.
PMID: 8895592
Nature. 1996 Nov 07;384(6604):7-9. doi: 10.1038/384007a0.

Developments in techniques of pharmaceutical chemistry are poised to revolutionize the design of drugs beyond previous expectations. But what are our current expectations and what does the future hold?

Cite
Petsko GA. For medicinal purposes. Nature. 1996;384(6604):7-9doi: 10.1038/384007a0.
Petsko, G. A. (1996). For medicinal purposes. Nature, 384(6604), 7-9. https://doi.org/10.1038/384007a0
Petsko, G A. "For medicinal purposes." Nature vol. 384,6604 (1996): 7-9. doi: https://doi.org/10.1038/384007a0
Petsko GA. For medicinal purposes. Nature. 1996 Nov 07;384(6604):7-9. doi: 10.1038/384007a0. PMID: 8895592.
Copy Download .nbib Format: NLM
Retrometabolic approaches for drug design and targeting.

Die Pharmazie

Bodor N.
PMID: 9266587
Pharmazie. 1997 Jul;52(7):491-4.

Retrometabolic drug design approaches incorporate targeting and metabolic considerations into the drug design process and represent a novel, systematic methodology for the design of safe, localized compounds. Two major design concepts aimed to increase the therapeutic index (the activity/toxicity...

Cite
Bodor N. Retrometabolic approaches for drug design and targeting. Pharmazie. 1997;52(7):491-4
Bodor, N. (1997). Retrometabolic approaches for drug design and targeting. Die Pharmazie, 52(7), 491-4.
Bodor, N. "Retrometabolic approaches for drug design and targeting." Die Pharmazie vol. 52,7 (1997): 491-4.
Bodor N. Retrometabolic approaches for drug design and targeting. Pharmazie. 1997 Jul;52(7):491-4. PMID: 9266587.
Copy Download .nbib Format: NLM
Chemoproteomics as a basis for post-genomic drug discovery.

Drug discovery today

Beroza P, Villar HO, Wick MM, Martin GR.
PMID: 12546968
Drug Discov Today. 2002 Aug 01;7(15):807-14. doi: 10.1016/s1359-6446(02)02371-1.

The large number of small organic compounds now available for drug-lead screening has led to numerous methods for classifying molecular similarity and diversity, the aim being to restore a balance between the quantity and drug-like quality of compounds in...

Cite
Beroza P, Villar HO, Wick MM, et al. Chemoproteomics as a basis for post-genomic drug discovery. Drug Discov Today. 2002;7(15):807-14doi: 10.1016/s1359-6446(02)02371-1.
Beroza, P., Villar, H. O., Wick, M. M., & Martin, G. R. (2002). Chemoproteomics as a basis for post-genomic drug discovery. Drug discovery today, 7(15), 807-14. https://doi.org/10.1016/s1359-6446(02)02371-1
Beroza, Paul, et al. "Chemoproteomics as a basis for post-genomic drug discovery." Drug discovery today vol. 7,15 (2002): 807-14. doi: https://doi.org/10.1016/s1359-6446(02)02371-1
Beroza P, Villar HO, Wick MM, Martin GR. Chemoproteomics as a basis for post-genomic drug discovery. Drug Discov Today. 2002 Aug 01;7(15):807-14. doi: 10.1016/s1359-6446(02)02371-1. PMID: 12546968.
Copy Download .nbib Format: NLM
Fuelling the pipeline.

Nature reviews. Drug discovery

[No authors listed]
PMID: 12120500
Nat Rev Drug Discov. 2002 Mar;1(3):167. doi: 10.1038/nrd767.

Drug pipelines need to be fed, not just with promising compounds, but also with promising scientists. Despite the high-tech nature of the enterprise, the skills most in demand when companies are recruiting can often be the most traditional.

Cite
Fuelling the pipeline. Nat Rev Drug Discov. 2002;1(3):167doi: 10.1038/nrd767.
(2002). Fuelling the pipeline. Nature reviews. Drug discovery, 1(3), 167. https://doi.org/10.1038/nrd767
"Fuelling the pipeline." Nature reviews. Drug discovery vol. 1,3 (2002): 167. doi: https://doi.org/10.1038/nrd767
Fuelling the pipeline. Nat Rev Drug Discov. 2002 Mar;1(3):167. doi: 10.1038/nrd767. PMID: 12120500.
Copy Download .nbib Format: NLM
Drug discovery.

Drug design and discovery

Olson G.
PMID: 11469749
Drug Des Discov. 2001;17(3):191.

No abstract available.

Cite
Olson G. Drug discovery. Drug Des Discov. 2001;17(3):191
Olson, G. (2001). Drug discovery. Drug design and discovery, 17(3), 191.
Olson, G. "Drug discovery." Drug design and discovery vol. 17,3 (2001): 191.
Olson G. Drug discovery. Drug Des Discov. 2001;17(3):191. PMID: 11469749.
Copy Download .nbib Format: NLM
Role of the development scientist in compound lead selection and optimization.

Journal of pharmaceutical sciences

Venkatesh S, Lipper RA.
PMID: 10688744
J Pharm Sci. 2000 Feb;89(2):145-54. doi: 10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6.

The R&D process for bringing drugs from discovery laboratories to the marketplace is undergoing rapid change, as enabled by new technologies and as demanded by the global pharmaceutical business environment. One consequence of the accelerated R&D paradigm is a...

Cite
Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci. 2000;89(2):145-54doi: 10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6.
Venkatesh, S., & Lipper, R. A. (2000). Role of the development scientist in compound lead selection and optimization. Journal of pharmaceutical sciences, 89(2), 145-54. https://doi.org/10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6
Venkatesh, S, and Lipper, R A. "Role of the development scientist in compound lead selection and optimization." Journal of pharmaceutical sciences vol. 89,2 (2000): 145-54. doi: https://doi.org/10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6
Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J Pharm Sci. 2000 Feb;89(2):145-54. doi: 10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6. PMID: 10688744.
Copy Download .nbib Format: NLM
[New approach in drug designing: molecular-targeted drugs].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine

Tsuruo T.
PMID: 12655675
Nihon Naika Gakkai Zasshi. 2002 Dec 10;91(12):3401-7.

No abstract available.

Cite
Tsuruo T. [New approach in drug designing: molecular-targeted drugs]. Nihon Naika Gakkai Zasshi. 2002;91(12):3401-7
Tsuruo, T. (2002). [New approach in drug designing: molecular-targeted drugs]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 91(12), 3401-7.
Tsuruo, Takashi. "[New approach in drug designing: molecular-targeted drugs]." Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine vol. 91,12 (2002): 3401-7.
Tsuruo T. [New approach in drug designing: molecular-targeted drugs]. Nihon Naika Gakkai Zasshi. 2002 Dec 10;91(12):3401-7. Japanese. PMID: 12655675.
Copy Download .nbib Format: NLM
Applications of biomolecular NMR to drug discovery.

Drug design and discovery

Fry DC, Emerson SD.
PMID: 10928447
Drug Des Discov. 2000;17(1):13-33.

No abstract available.

Cite
Fry DC, Emerson SD. Applications of biomolecular NMR to drug discovery. Drug Des Discov. 2000;17(1):13-33
Fry, D. C., & Emerson, S. D. (2000). Applications of biomolecular NMR to drug discovery. Drug design and discovery, 17(1), 13-33.
Fry, D C, and Emerson, S D. "Applications of biomolecular NMR to drug discovery." Drug design and discovery vol. 17,1 (2000): 13-33.
Fry DC, Emerson SD. Applications of biomolecular NMR to drug discovery. Drug Des Discov. 2000;17(1):13-33. PMID: 10928447.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 230 entries